Steve Schonfeld Schonfeld Strategic Advisors
Steve Schonfeld is the founder of Schonfeld Strategic Advisors, a multi-manager investment firm with roots in proprietary trading. Schonfeld allocates capital across quantitative and discretionary strategies with an emphasis on risk controls and diversification of return streams. The firm is a major name in the multi-strategy hedge fund landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$5.4B |
| 2 |
NVIDIA
NVDA
|
+$388M |
| 3 |
Microsoft
MSFT
|
+$182M |
| 4 |
Amazon
AMZN
|
+$177M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$163M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$213M |
| 2 |
Broadcom
AVGO
|
+$103M |
| 3 |
Union Pacific
UNP
|
+$100M |
| 4 |
ETHA
iShares Ethereum Trust ETF
ETHA
|
+$89.9M |
| 5 |
Marvell Technology
MRVL
|
+$89.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.68% |
| 2 | Industrials | 8.46% |
| 3 | Financials | 6.55% |
| 4 | Consumer Discretionary | 5.99% |
| 5 | Healthcare | 5.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Workiva
WK
$4.02B
| $597K | ﹤0.01% |
6,927
-11,218
| -62% | -$993K |
|
|
EMIS
1327
Emmis Acquisition Corp
EMIS
| $597K | ﹤0.01% |
+59,900
| New | +$597K |
|
1328
Bio-Rad Laboratories Class A
BIO
$10.1B
| $597K | ﹤0.01% |
1,971
-299
| -13% | -$93.3K |
|
|
LATA
1329
Galata Acquisition Corp II
LATA
| $596K | ﹤0.01% |
+59,930
| New | +$597K |
|
|
NXH
1330
Neighborhood Intelligence Inc
NXH
$374M
| $595K | ﹤0.01% |
+108,885
| New | +$790K |
|
1331
Insight Enterprises
NSIT
$4.41B
| $585K | ﹤0.01% |
+7,182
| New | +$674K |
|
1332
Myriad Genetics
MYGN
$295M
| $584K | ﹤0.01% |
95,035
+39,586
| +71% | +$287K |
|
1333
Vodafone
VOD
$36.7B
| $581K | ﹤0.01% |
44,008
+32,728
| +290% | +$396K |
|
1334
CALL
VF Corp
VFC
$5.46B
| $579K | ﹤0.01% |
+32,000
| New | +$519K |
|
|
1335
PUT
VF Corp
VFC
$5.46B
| $579K | ﹤0.01% |
+32,000
| New | +$519K |
|
|
GLIBK
1336
Liberty Capital Corp Series C GCI Group Common Stock
GLIBK
$1.03B
| $578K | ﹤0.01% |
15,543
+2,740
| +21% | +$96.2K |
|
1337
Crown Castle
CCI
$32.4B
| $576K | ﹤0.01% |
6,484
-264,725
| -98% | -$24.3M |
|
|
NB
1338
NioCorp Developments
NB
$636M
| $576K | ﹤0.01% |
108,630
-158,670
| -59% | -$1.09M |
|
1339
Neurogene
NGNE
$822M
| $575K | ﹤0.01% |
+27,894
| New | +$694K |
|
|
CHECU
1340
Chenghe Acquisition III Co Units
CHECU
| $574K | ﹤0.01% |
+57,164
| New | +$572K |
|
1341
AerCap
AER
$23.2B
| $573K | ﹤0.01% |
3,987
-12,090
| -75% | -$1.6M |
|
1342
Lantheus
LNTH
$6.61B
| $573K | ﹤0.01% |
+8,610
| New | +$501K |
|
|
MZTI
1343
The Marzetti Company
MZTI
$3.19B
| $570K | ﹤0.01% |
3,464
-4,882
| -58% | -$815K |
|
1344
LCI Industries
LCII
$2.52B
| $567K | ﹤0.01% |
4,669
-8,960
| -66% | -$953K |
|
1345
Skyworks Solutions
SWKS
$9.66B
| $566K | ﹤0.01% |
8,928
-314,776
| -97% | -$22M |
|
1346
Peoples Bancorp
PEBO
$1.43B
| $565K | ﹤0.01% |
+18,819
| New | +$559K |
|
1347
Trinity Industries
TRN
$2.34B
| $565K | ﹤0.01% |
21,359
+888
| +4% | +$24.1K |
|
1348
Village Farms International
VFF
$333M
| $561K | ﹤0.01% |
+153,719
| New | +$535K |
|
1349
Critical Metals Corp
CRML
$1.12B
| $560K | ﹤0.01% |
+80,661
| New | +$880K |
|
1350
Cavco Industries
CVCO
$4.54B
| $559K | ﹤0.01% |
947
-37,770
| -98% | -$21.4M |
|
Similar funds
Steve Schonfeld's Q4 2025 Portfolio in Review
As of Q4 2025, Steve Schonfeld held 2,774 positions worth $22.6B, up 28% from $17.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Steve Schonfeld deployed $4.53B of net new capital in Q4 2025, opening 620 new positions and adding to 589 existing holdings. Its largest new stake was Medline Inc: 1,945,050 shares worth $81.7M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 14% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $213M trimmed.
- Steve Schonfeld's largest Q4 2025 buy was Medline Inc: 1,945,050 shares worth $81.7M.
- Steve Schonfeld added most to iShares Core S&P 500 ETF in Q4 2025, an estimated $5.4B increase.
- Steve Schonfeld's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $213M.
- Steve Schonfeld fully exited Southwest Airlines in Q4 2025, selling an estimated $73.9M.
- Steve Schonfeld's ten largest holdings make up 41% of its $22.6B portfolio in Q4 2025.
- Steve Schonfeld opened 620 new positions and closed 789 in Q4 2025.
- Steve Schonfeld's portfolio value rose 28% quarter-over-quarter to $22.6B.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.